Thus, effective NK cell activation and recruitment by CD123-NKCE were associated with a pharmacodynamics effect of CD123+ cell depletion in human PBMCs, but without marked proinflammatory cytokine release at up to 10 μg ml−1 dose (68 nM), suggesting that NKCEs have a better benefit/risk profile than TCEs for the treatment of AML. Here, IL3RA is linked to acute myeloid leukemia.